FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3176593039> ?p ?o ?g. }

• W3176593039 endingPage "100978" @default.
• W3176593039 startingPage "100978" @default.
• W3176593039 abstract "Scalp hair loss (alopecia) in women is a common ageing and senescing condition. It usually presents as androgenetic alopecia (AGA) or telogen effluvium (TE) and often has pronounced psychological consequences. ALRV5XR is a novel treatment aiming to regenerate a normal hair phenotype by targeting multiple molecular pathways linked to hair growth promotion and hair follicle stem cell activation. The primary objectives of this 24-week trial were to evaluate the safety and efficacy of ALRV5XR in terminal hair (TH) regrowth in women with AGA or TE.This randomised, double-blind, placebo-controlled trial was performed in a USA community clinic. Healthy women 18-65 years of age with AGA or TE of Ludwig classification I-II and Fitzpatrick skin type I-VI were enrolled. They were allocated in a 1:1 ratio into ALRV5XR or placebo treatment groups using a random number table. Masked dermatologist assessments, phototrichograms and blood samples were obtained at baseline, 12 and 24 weeks. Subjects were given a masked treatment regimen of oral capsules, shampoo, conditioner and follicle serum for daily administration. Main outcomes were absolute and per cent changes in TH density and response rates. The trial was registered with clinicaltrials.gov (NCT04450602) and is completed.46 subjects (23 ALRV5XR, 23 placebo) were enrolled between April 3 and October 20, 2018. Five subjects dropped out and two were non-compliant. Thirty-nine subjects completed the trial (18 ALRV5XR, 21 placebo). At 24 weeks, the absolute change in TH density improved by 30·1THs/cm2 (95% CI: 15·1-45·1; p=0·0002), and the relative density increased by 19·7% (95% CI: 8·0%-31·4%; p=0·0016). The odds ratio for being a responder (≥0 change) was 2·7. Efficacy increased 133% from week 12 to 24. Efficacy outcomes were similar in AGA and TE subjects. 66·7% of the ALRV5XR group responded by regrowing 40THs/cm2 or more hair. No adverse events were reported.In women with AGA or TE, ALRV5XR treatment significantly increased hair regrowth without adverse events. ALRV5XR displayed a multi-fold improved efficacy and response rate when compared to published trials of standard therapy. Progressive acceleration of TH regrowth suggests regeneration of the structure and function of non-productive telogen follicles and prolonged treatment may restore a normal hair phenotype." @default.
• W3176593039 created "2021-07-05" @default.
• W3176593039 creator A5038156803 @default.
• W3176593039 creator A5046104461 @default.
• W3176593039 creator A5063039730 @default.
• W3176593039 creator A5064134740 @default.
• W3176593039 creator A5074969031 @default.
• W3176593039 creator A5083043647 @default.
• W3176593039 creator A5084408887 @default.
• W3176593039 date "2021-07-01" @default.
• W3176593039 modified "2023-10-15" @default.
• W3176593039 title "Safety and efficacy of ALRV5XR in women with androgenetic alopecia or telogen effluvium: A randomised, double-blinded, placebo-controlled clinical trial" @default.
• W3176593039 cites W1783755519 @default.
• W3176593039 cites W1991258355 @default.
• W3176593039 cites W2014725607 @default.
• W3176593039 cites W2042964408 @default.
• W3176593039 cites W2073177538 @default.
• W3176593039 cites W2082645238 @default.
• W3176593039 cites W2092493771 @default.
• W3176593039 cites W2118535696 @default.
• W3176593039 cites W2128022177 @default.
• W3176593039 cites W2130057699 @default.
• W3176593039 cites W2156757464 @default.
• W3176593039 cites W2171842245 @default.
• W3176593039 cites W2264715967 @default.
• W3176593039 cites W2266122743 @default.
• W3176593039 cites W2322717924 @default.
• W3176593039 cites W2509436176 @default.
• W3176593039 cites W2555751482 @default.
• W3176593039 cites W2605226576 @default.
• W3176593039 cites W2771059226 @default.
• W3176593039 cites W2805128965 @default.
• W3176593039 cites W2971355359 @default.
• W3176593039 cites W3015702846 @default.
• W3176593039 cites W3091969977 @default.
• W3176593039 cites W3120359666 @default.
• W3176593039 doi "https://doi.org/10.1016/j.eclinm.2021.100978" @default.
• W3176593039 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8249777" @default.
• W3176593039 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34235415" @default.
• W3176593039 hasPublicationYear "2021" @default.
• W3176593039 type Work @default.
• W3176593039 sameAs 3176593039 @default.
• W3176593039 citedByCount "6" @default.
• W3176593039 countsByYear W31765930392021 @default.
• W3176593039 countsByYear W31765930392022 @default.
• W3176593039 countsByYear W31765930392023 @default.
• W3176593039 crossrefType "journal-article" @default.
• W3176593039 hasAuthorship W3176593039A5038156803 @default.
• W3176593039 hasAuthorship W3176593039A5046104461 @default.
• W3176593039 hasAuthorship W3176593039A5063039730 @default.
• W3176593039 hasAuthorship W3176593039A5064134740 @default.
• W3176593039 hasAuthorship W3176593039A5074969031 @default.
• W3176593039 hasAuthorship W3176593039A5083043647 @default.
• W3176593039 hasAuthorship W3176593039A5084408887 @default.
• W3176593039 hasBestOaLocation W31765930391 @default.
• W3176593039 hasConcept C126322002 @default.
• W3176593039 hasConcept C141071460 @default.
• W3176593039 hasConcept C142724271 @default.
• W3176593039 hasConcept C16005928 @default.
• W3176593039 hasConcept C168563851 @default.
• W3176593039 hasConcept C197934379 @default.
• W3176593039 hasConcept C204787440 @default.
• W3176593039 hasConcept C27081682 @default.
• W3176593039 hasConcept C2776360568 @default.
• W3176593039 hasConcept C2778515351 @default.
• W3176593039 hasConcept C2781413609 @default.
• W3176593039 hasConcept C535046627 @default.
• W3176593039 hasConcept C71924100 @default.
• W3176593039 hasConceptScore W3176593039C126322002 @default.
• W3176593039 hasConceptScore W3176593039C141071460 @default.
• W3176593039 hasConceptScore W3176593039C142724271 @default.
• W3176593039 hasConceptScore W3176593039C16005928 @default.
• W3176593039 hasConceptScore W3176593039C168563851 @default.
• W3176593039 hasConceptScore W3176593039C197934379 @default.
• W3176593039 hasConceptScore W3176593039C204787440 @default.
• W3176593039 hasConceptScore W3176593039C27081682 @default.
• W3176593039 hasConceptScore W3176593039C2776360568 @default.
• W3176593039 hasConceptScore W3176593039C2778515351 @default.
• W3176593039 hasConceptScore W3176593039C2781413609 @default.
• W3176593039 hasConceptScore W3176593039C535046627 @default.
• W3176593039 hasConceptScore W3176593039C71924100 @default.
• W3176593039 hasLocation W31765930391 @default.
• W3176593039 hasLocation W31765930392 @default.
• W3176593039 hasLocation W31765930393 @default.
• W3176593039 hasOpenAccess W3176593039 @default.
• W3176593039 hasPrimaryLocation W31765930391 @default.
• W3176593039 hasRelatedWork W102754757 @default.
• W3176593039 hasRelatedWork W2085830368 @default.
• W3176593039 hasRelatedWork W2300110615 @default.
• W3176593039 hasRelatedWork W2517377425 @default.
• W3176593039 hasRelatedWork W2593683052 @default.
• W3176593039 hasRelatedWork W2601895326 @default.
• W3176593039 hasRelatedWork W2955139145 @default.
• W3176593039 hasRelatedWork W4249888343 @default.
• W3176593039 hasRelatedWork W4327681828 @default.
• W3176593039 hasRelatedWork W2130915320 @default.
• W3176593039 hasVolume "37" @default.
• W3176593039 isParatext "false" @default.

• next